GIKLY - GigaGen says novel mechanism of cancer candidate support superior anti-tumor activity

Meletios Verras/iStock via Getty Images Grifols ([[GIKLY]]) says that the novel mechanism of action of subsidiary GigaGen's anti-CTLA-4 drug candidate, GIGA-564, for cancer indications leads to superior anti-tumor activity and lower toxicity in a mouse model. GigaGen says that GIGA-564 differs from other anti-CTLA-4 therapies through reduced checkpoint inhibition. Bristol-Myers Squibb's Yerboy (ipilimumab) is a currently marketed anti-CTLA-4. "Current anti-CTLA-4s such as ipilimumab have shown promising results, but the majority of patients don’t see reduction of tumors and experience life-threatening toxicities," GigaGen CEO David Johnson said in a statement. The company says the data supports moving GIGA-546 into the clinic. Results were published in bioRxiv.

For further details see:

GigaGen says novel mechanism of cancer candidate support superior anti-tumor activity